Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9503430 | 0.78 | KDM4E (0.36) | SMN1; SMN2NPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL9479129 | 0.72 | — | — | |
| SCHEMBL3817613 | 0.72 | GAA (0.43) | SMN1; SMN2NPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL9224524 | 0.72 | P2RY1 (0.43) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3148442 | 0.72 | — | — | |
| SCHEMBL17547305 | 0.68 | — | — | |
| SCHEMBL9827215 | 0.64 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL11235845 | 0.63 | ALDH1A1 (0.42) | SMN1; SMN2NPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL31241304 | 0.63 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL9827332 | 0.62 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| EP-0316731-B1 | AZO DYES FROM 2-HYDRAZINOTHIAZOLE, THEIR USE IN DYEING AND PRINTING FIBRE MATERIALS, AND IN SUBLIMATION TRANSFER PRINTING | BAYER AG (DE) | 1993-05-19 | — | — | EP | disclosed |
| EP-0316731-A2 | Azo dyes from 2-hydrazinothiazole, their use in dyeing and printing fibre materials, and in sublimation transfer printing | BAYER AG (DE) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | SMN1; SMN2 4499/4885NPC1 1118/4885MEN1 3647/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | SMN1; SMN2 3100/4885NPC1 1470/4885MEN1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.